Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV amisulpride for prevention of postoperative nausea and vomiting in pediatric patients
2024-518778-15-00Phase 3Completed
- Sponsor
- Acacia Pharma Limited
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Acacia Pharma Limited. Primary endpoint: Complete Response (absence of PONV) during first 24 hours. Started Jan 2025; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2024-518778-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518778-15-00.